Efficacy of DNK333 in Patients With COPD and Cough
NCT01287325
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG:
DNK333 100 mg twice daily
DRUG:
Placebo
Sponsor
Novartis